Methods and compositions for treating neuropathies

Abstract

Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing neuropathies.

What is claimed is: 
     
         1 . A method of treating an axonopathy in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of an agent that acts by increasing NAD activity in neurons and/or supporting cells wherein the agent is selected from the group consisting of NADH, nicotinate adenine dinucleotide, nicotinate mononucleotide, quinolinic acid, quinolinate, nicotinic acid, nicotinamide, tryptophan and a combination thereof. 
     
     
         2 . A method according to  claim 1 , wherein the mammal is a human. 
     
     
         3 . A method according to  claim 1 , wherein the axonopathy is an axonopathy induced by a cytotoxic anticancer agent. 
     
     
         4 . A method according to  claim 1 , wherein the axonopathy is hereditary or congenital or associated with a neurodegenerative disease, a motor neuron disease, a neoplasia, an endocrine disorder, a metabolic disease, a nutritional deficiency, an autoimmune disease, a mechanical injury, a chemical or drug-induced injury, a thermal injury, a radiation injury, a nerve compression, a retinal or optic nerve disorder, mitochondrial dysfunction, progressive dementia, a demyelinating disease, ischemia and/or stroke, an infectious disease or an inflammatory disease. 
     
     
         5 . A method according to  claim 4 , wherein the retinal or optic nerve disorder is glaucoma, retinal ganglion degeneration, optic neuritis and/or degeneration, ischemic optic neuropathy, traumatic injury to the optic nerve, hereditary optic neuropathy, metabolic optic neuropathy, neuropathy due to a toxic agent, neuropathy caused by an adverse drug reaction, or neuropathy due to a vitamin deficiency. 
     
     
         6 . A method according to  claim 4 , wherein the axonopathy associated with mitochondrial dysfunction is an axonopathy resulting from oxidative damage, from mutations in mitochondrial proteins encoded in the mitochondrial genome, from mutations in mitochondrial proteins encoded in the nuclear genome, from exposure to toxins, or from the process of aging. 
     
     
         7 . A method according to  claim 1 , wherein the agent is NADH. 
     
     
         8 . A method according to  claim 1 , wherein the agent is nicotinate adenine dinucleotide. 
     
     
         9 . A method according to  claim 1 , wherein the agent is nicotinate mononucleotide. 
     
     
         10 . A method according to  claim 1 , wherein the agent is selected from the group consisting of quinolinic acid, quinolinate and a combination thereof. 
     
     
         11 . A method according to  claim 1 , wherein the agent is nicotinic acid. 
     
     
         12 . A method according to  claim 1 , wherein the agent is nicotinamide. 
     
     
         13 . A method according to  claim 1 , wherein the agent is tryptophan.